Conservation of the enzyme-like activity and biocompatibility of CeO2 nanozymes in simulated body fluids

Cerium oxide nanozymes (CeO(2)NZs) are attracting vast attention due to their antioxidant and catalytic properties and mimic the activities of multiple endogenous enzymes. However, as is the case for nanomedicines in general, the success in showing their unique medical applications has not been matched by an understanding of their pharmacokinetics, which is delaying their implementation in clinical settings. Furthermore, the data of their modifications in body fluids and the impact on their activity are scarce. Herein, two types of widely used CeO(2)NZs, electrostatically stabilized and coated with a mesoporous silica shell, were exposed to simulated saliva and lung, gastric and intestinal fluids, and cell culture media. Their physicochemical modifications and bioactivity were tracked over time up to 15 days combining the data of different characterization techniques and biological assays. The results show that the biocompatibility and antioxidant activity are retained in all cases despite the different evolution behaviors in different fluids, including agglomeration. This work provides an experimental basis from a pharmacokinetic perspective that supports the therapeutic effectiveness of CeO(2)NZs observed in vivo for the treatment of many conditions related to chronic inflammation and cancer, and suggests that they can be safely administered through different portals of entry including intravenous injection, oral ingestion or inhalation.

Automated summary

This study investigates the evolution behavior of two commonly used cerium oxide nanozymes (CeO(2)NZs) in different fluids. The results show that the biocompatibility and antioxidant activity of CeO(2)NZs are retained in all cases, despite the different behaviors observed in different fluids. This provides experimental evidence supporting the therapeutic effectiveness of CeO(2)NZs for the treatment of chronic inflammation and cancer.